Terlipressin vs other vasoactive drugs: Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome)
It is very uncertain whether terlipressin changes hepatorenal syndrome (Number of participants who did not achieve… compared with other vasoactive drugs (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Terlipressin vs other vasoactive drugs Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome) · people with cirrhosis and hepatorenal syndrome It is very uncertain whether terlipressin changes hepatorenal syndrome (Number of participants who did not achieve… compared with other vasoactive drugs (very low certainty). Terlipressin versus other vasoactive drugs for hepatorenal syndrome (2017) · Cochrane Headline outcomes only | RR 0.79 [0.63, 0.99] | 394 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.